FDA Announces Joint Meeting of Psychopharmacologic Drugs and Drug Safety Advisory Committees

Summary

The FDA is hosting a joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to provide public advice on regulatory issues, with a public comment period to follow.